<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297945</url>
  </required_header>
  <id_info>
    <org_study_id>HRA112025-002</org_study_id>
    <nct_id>NCT02297945</nct_id>
  </id_info>
  <brief_title>Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome</brief_title>
  <acronym>PROMPT</acronym>
  <official_title>Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HRA Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HRA Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, international phase III/IV study is to assess the efficacy
      and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks
      of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol
      (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will include Cushing disease patients with persistent or recurrent disease (after
      pituitary surgery) or who are newly diagnosed but are unsuitable for early surgery or wish to
      defer surgery. It will also include patients with ectopic ACTH syndrome (either occult, after
      surgery failure, or inoperable or metastatic) and patients with Cushing's syndrome from
      adrenal causes.

      The ability of metyrapone to normalize urinary free cortisol levels will be assessed during
      up to 36 weeks (9 months) of treatment. Patients participating in this study and who are
      controlled or close to the target at the end of a 3-months period may continue with an
      optional extension period of 6 months in which the long-term efficacy and safety profiles of
      metyrapone will be assessed. This extension study is intended to provide new findings to
      consolidate existing efficacy and safety data on metyrapone in the treatment of Cushing's
      syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of cortisol levels (urinary free cortisol)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cushing's Syndrome</condition>
  <arm_group>
    <arm_group_label>Metyrapone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metyrapone</intervention_name>
    <description>Single arm study</description>
    <arm_group_label>Metyrapone</arm_group_label>
    <other_name>Metopirone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients with endogenous Cushing's syndrome:

          -  Cushing disease patients with persistent or recurrent disease (after pituitary
             surgery) or who are newly diagnosed but are unsuitable for early surgery or wish to
             defer surgery;

          -  Patients with ectopic ACTH syndrome (either occult, after surgery failure, or
             inoperable or metastatic);

          -  Patients with Cushing's syndrome from adrenal causes

        Exclusion Criteria:

          1. Pseudo Cushing's syndrome

          2. Cyclic Cushing's syndrome defined by at least one normal UFC value among at least
             three 24-hour urinary sampling measurements over the previous 2 months

          3. Advanced adrenocortical carcinoma or ectopic ACTH secretion (EAS) secondary to a small
             cell lung carcinoma

          4. Life expectancy less than 3 months

          5. Pituitary or adrenal surgery or pituitary irradiation or surgery of the ACTH-secreting
             ectopic tumor or bilateral adrenalectomy planned before the week 12 visit

          6. Pituitary irradiation within the previous 5 years (for Cushing's disease patients)

          7. Enlarged pituitary adenoma (greater than 1 cm in vertical diameter and leaving less
             than 2 mm from the chiasma) or compression of the optic chiasma on the pituitary MRI
             for patients with Cushing's disease

          8. Severe uncontrolled hypertension (&gt;180/110 mmHg) despite anti-hypertensive therapy
             (for otherwise eligible patients, blood pressure medication may be adjusted to meet
             this criterion)

          9. Severe hypokalemia (&lt; 2.5 mmol/L) despite corrective measures

         10. White blood cell counts &lt;3 x 109 /L; hemoglobin &lt;10 g/dL; platelets &lt;100 x 109 /L

         11. Any other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that in the judgment of the investigator, would present excess risk
             associated with study participation or study drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Driessens, Dr</last_name>
      <phone>+32 2 5553131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Saint Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maiter, Prof</last_name>
      <phone>+32 2 764 11 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beckers, Prof</last_name>
      <phone>+32 4 242 52 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tina Kienitz, Dr</last_name>
      <phone>+49 30 45050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Führer-Sakel, Prof</last_name>
      <phone>+49 201 7230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Munich university</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beuschlein, Prof</last_name>
      <phone>+49 89 440052100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fassnacht, Prof</last_name>
      <phone>+49 931 2010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State health center</name>
      <address>
        <city>Budapest</city>
        <zip>10062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laszlo Kovacs, Dr</last_name>
    </contact>
    <contact_backup>
      <phone>06 465-1800 3.</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. Belgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toth, Dr</last_name>
      <phone>+36 1 266 0926</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Endre Nagy, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pecs</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mezosi, Dr</last_name>
      <phone>+36 72 501 599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zsuzsanna Valkusz, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Luigi Gonzaga Hospital, University of Turin</name>
      <address>
        <city>Orbassano</city>
        <state>Turin</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Terzolo, Prof</last_name>
      <phone>+39 011 90261</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loli, Dr</last_name>
      <phone>+39 02 6444.1</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luca IRCCS Istituto Auxologico Italiano</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cavagnini, Prof</last_name>
      <phone>+39 02 619111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S. Giuseppe Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arosio, Dr</last_name>
      <phone>+39 0575 37341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federico II University</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pivonello, Prof</last_name>
      <phone>+39 081 253 1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boscaro, Prof</last_name>
      <phone>+39 049 827 5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Turin</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghigo, Dr</last_name>
      <phone>+39 011 670 6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Jarzab, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Motyka, Dr</last_name>
      <phone>+48 12 424 70 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marek Bolanowski, Prof</last_name>
      <phone>+48 71 327 09 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanzu, Dr</last_name>
      <phone>+34 932 27 54 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Ribera</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fajardo, Dr</last_name>
      <phone>+34 962 45 81 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Numune Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dilek Berker, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul UMF</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baris Akinci, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayıs University Medical Faculty</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aysegül Atmaca, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik University</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mustafa Koçak, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metyrapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

